Evidence map›Paper›PMID 41795606›Full record

ArticleCancer reports (Hoboken, N.J.)2026

Expanding the Anatomical Distribution of PRRX1::KMT2D Fusion Mesenchymal Neoplasms: A Rare Mediastinal Case Report.

Weixiang Zhong, Yu Deng, Ke Sun

Abstract readCase Reports
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Weixiang ZhongDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0002-5493-893X
Yu DengDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0002-7513-1297
Ke SunDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0002-3789-3143

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPRRX1-rearranged mesenchymal neoplasms are rare soft tissue tumors with a predilection for the superficial subcutaneous tissue. The PRRX1::KMT2D fusion variant is exceptionally rare, with only three previously reported cases, all of which were located in the intermuscular regions. However, its occurrence in deep visceral sites has not been documented. CASE: A 62-year-old woman was admitted after a routine physical examination revealed a space-occupying lesion in the left thoracic cavity. Contrast-enhanced CT showed a mixed-density mass (10.4 × 8.1 × 3.8 cm) at the left cardiophrenic angle. The patient underwent complete thoracoscopic resection. Intraoperative frozen sections suggested a spindle cell tumor. Postoperative pathology, immunohistochemistry, and targeted RNA sequencing identified a PRRX1::KMT2D fusion mesenchymal neoplasm. At 18-month follow-up, no recurrence or progression was observed.

conclusionThis is the first reported case of a PRRX1::KMT2D fusion mesenchymal neoplasm arising in the mediastinum, which expands the anatomical spectrum of this emerging entity. Our findings underscore the importance of integrating morphological, immunohistochemical, and molecular approaches for accurate diagnosis, particularly in deep-seated and unusual locations.

Indexed as

Homeodomain ProteinsMediastinal NeoplasmsOncogene Proteins, FusionFemaleHumansMiddle AgedThoracoscopyTomography, X-Ray ComputedHomeodomain ProteinsOncogene Proteins, FusionPRRX1 protein, humancase reportgene fusionmediastinummesenchymal neoplasmPRRX1::KMT2D

Identifiers

PMID41795606
PMCPMC12967484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.